IM
Immunic, Inc.
IMUX · NASDAQ
$9.37 -13.64% (-$1.48)
1M -42.94%
Market Cap $127.6M
P/E Ratio -
Div. Yield -
ROE 157.89%
Bulios Fair Price
$8.1
13.6% downside
Current Price
$9.37
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IMUX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 1.00x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 91.99%
ROE 157.89%
ROA 70.09%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 5.05x
Int. coverage N/A
Stability
59 /100
Moderate Beta 1.41x
EPS volatility 7.52%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IMUX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Erik Lundgren
Employees
100
Headquarters
New York City
Upcoming events
12 NOV
Earnings
Upcoming earnings report